ProShares UltraShort NASDAQ Biotechnology
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
16.55% less ownership
Funds ownership: 29.65% [Q4 2024] → 13.1% (-16.55%) [Q1 2025]
33% less funds holding
Funds holding: 6 [Q4 2024] → 4 (-2) [Q1 2025]
57% less capital invested
Capital invested by funds: $1.08M [Q4 2024] → $464K (-$615K) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for BIS.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Neutral
ETF Trends
1 month ago
Top Performing Leveraged/Inverse ETFs: 05/11/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Neutral
ETF Trends
6 months ago
Top Performing Leveraged/Inverse ETFs: 11/17/2024
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Charts implemented using Lightweight Charts™